权益分类	功能权益	普通用户	{{item.name}}会员
{{category.name}}	{{benefitItem.name}}

Injectable Hydrogel Electrodes to Prevent Ventricular Arrhythmias

可注射水凝胶电极预防室性心律失常

基本信息

批准号：
10583238
负责人：
Elizabeth Marie Cosgriff-Hernandez
金额：
$ 56.19万
依托单位：
UNIVERSITY OF TEXAS AT AUSTIN
依托单位国家：
美国
项目类别：
财政年份：
2023
资助国家：
美国
起止时间：
2023-01-05 至 2026-12-31
项目状态：
未结题

来源：
https://reporter.nih.gov/project-details/10583238
关键词：
Anti-Arrhythmia Agents Area Biocompatible Materials Cardiac Cardiac ablation Cardiomyopathies Catheters Cessation of life Chemistry Cicatrix Clinical Contrast Media Coronary Vessels Custom Development Disease Electric Countershock Electric Stimulation Electrodes Electrophysiology (science)Engineering Frequencies Genetic Complementation Test Grant Heart Heterogeneity Human Hydrogels Implantable Defibrillators In Situ In Vitro Injectable Lead Length Life Methods Modeling Myocardial Infarction Myocardial tissue Myocardium Pacemakers Pain Pain Threshold Painless Physiologic pulse Positioning Attribute Quality of life Research Safety Science Shock Site Source Stimulus Structure of left gastric vein Sudden Death Surface System Technology Thick Tissues United States Venous Venous system Ventricular Ventricular Arrhythmia Work cardiac resynchronization therapy clinical translation design efficacy validation flexibility flexible electronics grasp heart rhythm improved in vivo in vivo evaluation innovation minimally invasive novel porcine model prevent psychological trauma safety assessment standard of care sudden cardiac death tool

项目摘要

Injectable Hydrogel Electrodes to Prevent Ventricular Arrhythmias In the United States, sudden cardiac death accounts for 350,000 deaths per year with the leading cause being lethal ventricular arrhythmias. The underlying electrophysiologic derangement mechanistically responsible for ventricular arrhythmias is delayed conduction velocity in scarred or otherwise diseased myocardium. Access to the smaller vessels and tributaries that cross over scarred region of the heart could provide improved pacing; however, there are no pacing leads small enough to navigate these smaller tributaries. In this research, we propose a novel method to treat and manage ventriculararrhythmias – developmentof a newconductive material that can fill both large and small coronary vessels and convert these tributaries into flexible electrodes to restore capture across regions of scarring. Our collaborative team that combines clinical expertise (Razavi) and biomaterial science (Cosgriff-Hernandez) has demonstrated early feasibility of pacing myocardium with an in situ curing hydrogel in a pig model. We plan to build on this initial proof of concept to develop a combined material and delivery system that can interface with existing pacemaker technology to greatly expand their capability to treat ventricular arrhythmias. Upon successful completion of these aims, we will have utilized a battery of in vitro and in vivo tests to establish the safety and efficacy of this new injectable hydrogel electrode. Confirmation of increased activation area as compared to standard-of-care single point pacing will validate the efficacy of this innovative approach to eliminate the conduction delay in scarred myocardium that results in lethal ventricular arrhythmias. We will use a post-myocardial infarct model to demonstrate that hydrogel electrode pacing reduces the frequency of ventricular arrhythmias and defibrillation shocks. Painless stimulation of wide areas of the heart using planar wavefront propagation from these hydrogel electrodes provides a new cardiac resynchronization therapy that will alter the landscape of cardiac rhythm management.

可注射水凝胶电极预防室性心律失常在美国，每年有35万人死于心脏性猝死，其主要原因是致命性室性心律失常。潜在的电生理紊乱在机制上负责室性心律失常是疤痕或其他病变心肌的传导速度延迟。进入穿过心脏疤痕区域的较小血管和支流可以提供更好的起搏；然而，没有足够小的步行线来通过这些较小的支流。在这项研究中，我们提出一种治疗和管理室性心律失常的新方法--新型导电材料的开发它可以填充大小冠状动脉，并将这些支流转换为灵活的电极，以恢复在伤痕累累的区域进行捕捉。我们的协作团队结合了临床专业知识(Razavi)和生物材料科学(Cosgriff-Hernandez)已经证明了用原位心脏起搏的早期可行性。在猪模型中固化水凝胶。我们计划在最初的概念验证的基础上开发一种组合材料和传输系统，可以与现有的起搏器技术对接，以极大地扩展其能力治疗室性心律失常。在成功完成这些目标后，我们将利用一组体外培养的并进行体内试验，以确定这种新型可注射水凝胶电极的安全性和有效性。确认与标准护理单点起搏相比，激活面积的增加将验证这一方法的有效性消除瘢痕心肌传导延迟的创新方法，这种延迟会导致致命的心室心律不齐。我们将使用心肌梗死后模型来证明水凝胶电极起搏可以减少室性心律失常和除颤电击的频率。心脏大范围的无痛刺激利用这些水凝胶电极的平面波前传播提供了一种新的心脏再同步化将改变心律管理格局的治疗。